{"filings":[{"id":554316,"accession_number":"0001104659-26-064500","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2026-05-20T20:06:01+00:00","items":["1.01","9.01"],"status":"ready","headline":"GridAI settles $1.03M debt with $800K cash and 71,482 common shares at $3.25/share","event_type":"debt","confidence":"high","bullets":["Settlement resolves $1,032,315 owed under Revolving Loan Agreement; avoids default demand.","Cash payment of $800,000 covers principal ($700K) and $100K interest; 71,482 shares satisfy remaining $232,315 interest.","Shares issued at $3.25 per share (5-day VWAP); lender releases all claims upon closing.","Closing must occur within 10 days; otherwise agreement terminates and debt remains enforceable.","Company had previously disclosed default demand letter from lender on April 1, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442362,"accession_number":"0001104659-26-061136","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2026-05-14T20:01:34+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"GridAI Technologies Corp. raises ~$7.8M in private placement of common stock and warrants","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$2.54M: 74,000 shares, 1,196,001 pre-funded warrants at $0.00001, and 1,270,001 common warrants at $2.00/unit.","Gross proceeds of ~$5.25M: 87,260 shares, 1,745,199 pre-funded warrants, and 1,832,459 common warrants at $2.865/unit.","Net proceeds for general corporate purposes, working capital, and debt repayment. Closing expected May 18, 2026.","Common warrants exercise prices range $2.56–$2.89 per share, expire five years after resale registration effective date.","Registration rights agreement: file resale registration statement within 15 days after closing; 80% of $5.25M proceeds deferred until SEC effectiveness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94028,"accession_number":"0001104659-26-055628","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"GridAI regains Nasdaq compliance after filing delinquent 2025 10-K","event_type":"regulatory","confidence":"high","bullets":["Filed its 2025 Form 10-K on May 1, 2026, which was past the original due date.","Received deficiency letter on April 22, 2026 for failure to file periodic reports.","Nasdaq confirmed on May 4, 2026 that Company has regained compliance.","The matter is closed; no further action required per Nasdaq notification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94027,"accession_number":"0001104659-26-050499","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"GridAI receives Nasdaq notice for late 10-K filing; 60-day compliance plan deadline","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency letter on April 22, 2026 for failing to file FY2025 10-K by deadline.","Must submit compliance plan by June 22, 2026; Nasdaq may grant extension to October 12, 2026.","Delay attributed to complex accounting review of recent Grid AI Corp acquisition.","If plan rejected, company can appeal to Nasdaq hearings panel; delisting risk remains.","Company intends to file 10-K as soon as possible and regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94026,"accession_number":"0001104659-26-048549","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["2.04"],"status":"ready","headline":"GridAI receives loan default demand for $1.01M from lender","event_type":"debt","confidence":"high","bullets":["Demand letter received April 1, 2026, asserts default on $700,000 principal under Revolving Loan Agreement.","Total demanded sum of $1,014,675 includes principal, interest, and a 20% default penalty.","Company is evaluating the matter and is in active discussions with the lender."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94025,"accession_number":"0001104659-26-042177","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K/A","filed_at":"2026-04-13T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"GridAI Technologies provides acquired GridAI audited financials: $3.3M net loss, going concern","event_type":"other_material","confidence":"high","bullets":["GridAI net loss of $5.3M for inception-to-Sept 2025; $3.3M loss attributable to GridAI on $139K revenue.","Total assets $2.2M vs current liabilities $8.7M; working capital deficit of $7.6M.","Cash only $333K; $7.0M deferred consideration payable due from GridAI's AMPx acquisition.","Auditor flags substantial doubt about going concern; negative equity of $6.5M.","GridAI acquired 51% of AMPx UK Holdings on Feb 28, 2025; deal closed Sept 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106090,"accession_number":"0001104659-26-001755","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"GridAI completes rescission of ImmunogenX acquisition, removes $83.2M in assets","event_type":"other_material","confidence":"high","bullets":["Rescission completed Dec 31, 2025; Immuno LLC is no longer a subsidiary.","Pro forma total assets as of Sep 30, 2025: $52.2M (down from $135.4M).","Pro forma net loss from continuing ops for nine months ended Sep 30, 2025: $2.59M, diluted EPS -$1.77.","Removed 11,777,418 shares of Series G Preferred Stock issued to IMGX as part of rescission.","Pro forma net loss from continuing ops for year ended Dec 31, 2024: $15.62M, diluted EPS -$4.62."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122384,"accession_number":"0001104659-25-124213","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"GridAI appoints Jason D. Sawyer as permanent CEO; new consulting agreement with $25k/mo base, RSUs, and severance terms","event_type":"leadership","confidence":"high","bullets":["Jason D. Sawyer appointed permanent CEO effective Dec 19, 2025, transitioning from interim role.","Amended consulting agreement with Access Alternative Group for CEO services; initial 2-year term renewable yearly.","Base cash compensation $25,000/month retroactive to Oct 1, 2025; plus $20,000/quarter for Nasdaq compliance.","One-time payment of $150,000 + 400,000 shares upon shareholder approval of Grid AI Corp acquisition.","RSUs for 1,000,000 shares vesting quarterly in 2026; accelerate on termination without cause or change of control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122383,"accession_number":"0001104659-25-118524","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["1.01","5.02","5.03","8.01","9.01"],"status":"ready","headline":"GridAI director Corbett resigns citing governance concerns; ticker changes to GRDX","event_type":"leadership","confidence":"high","bullets":["Director Eric Corbett resigned due to disagreements over financial statement accuracy, GRID AI due diligence, and press release quality.","Director Richard Paolone also resigned; received $500K separation agreement and legal fees.","Name changed to GridAI Technologies Corp and ticker to GRDX effective Dec 1, 2025.","Corbett's letter flagged potentially inaccurate financial statements and misleading press releases disseminated to the market.","Name change follows acquisition of GRID AI Corp; board committees reconstituted with Borkowski, Uppal, Pursglove."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122382,"accession_number":"0001104659-25-107715","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GridAI stockholders waive board appointment rights pending shareholder approval","event_type":"other_material","confidence":"high","bullets":["GridAI stockholders waived right to appoint two directors to Entero board until shareholder vote.","Waiver relates to Section 5.09 of the Share Exchange Agreement dated Sept 30, 2025.","The original agreement was filed on Form 8-K on Oct 6, 2025.","Company must hold a shareholder meeting to approve the appointments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122381,"accession_number":"0001104659-25-104917","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-10-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nasdaq confirms Entero Therapeutics regains compliance with equity rule","event_type":"regulatory","confidence":"high","bullets":["Nasdaq letter dated Oct 28, 2025 confirms company meets $2.5M minimum stockholders' equity requirement.","Company previously reported negative equity of ($3.87M) in 10-K; received extension until Oct 8, 2025.","Compliance achieved via share exchange with GridAI Corp, disclosed in Oct 6, 2025 8-K.","Nasdaq warned that failure to maintain compliance in next periodic report may trigger delisting proceedings.","Company's stock (ENTO) continues trading on Nasdaq Capital Market without immediate delisting risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122380,"accession_number":"0001104659-25-101519","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Entero Therapeutics enters up to $5M securities purchase agreement with initial $500k closing","event_type":"debt","confidence":"high","bullets":["Initial closing of $500k non-interest bearing promissory note due one year and one day from issuance.","Warrants to purchase up to 1.52M shares at $2.50/share, exercisable after stockholder approval.","Company may hold subsequent closings for remaining $4.5M through Final Closing Date.","Proceeds for general corporate purposes, including working capital and potential acquisitions.","Note is not convertible; maturity may be extended in one-year increments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122379,"accession_number":"0001104659-25-097138","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["1.01","2.01","3.02","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Entero Therapeutics acquires GridAI in share exchange; former GridAI holders to own 82.5% of diluted ENTO","event_type":"m_and_a","confidence":"high","bullets":["Acquired 100% of GridAI for 424,348 common shares (19.99% of outstanding) and 38,801,546 Series H convertible shares.","Upon conversion (subject to shareholder approval), former GridAI stockholders will own 82.5% of ENTO on a fully diluted basis.","GridAI is a grid-edge AI platform managing behind-the-meter assets; over $50M invested since 2019.","ENTO must raise at least $3M in gross proceeds within 30 days post-closing and maintain $2M cash minimum.","Former GridAI shareholders get right to designate 2 directors initially, eventually 5 of 7 board seats."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139091,"accession_number":"0001104659-25-089562","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Entero Therapeutics appoints Jason D. Sawyer as Interim CEO under consulting agreement at $12,500/month","event_type":"leadership","confidence":"high","bullets":["Jason D. Sawyer appointed Interim CEO via consulting agreement with Access Alternative Group S.A., effective Sept 4, 2025.","Compensation set at $12,500 per month; agreement renewable month-to-month at Company's discretion.","Company to indemnify Sawyer as CEO to fullest extent under Delaware law; D&O insurance maintained.","Prior interim CEO appointment disclosed Sept 9; formal consulting agreement entered Sept 8."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139090,"accession_number":"0001104659-25-088663","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["1.02","5.02","9.01"],"status":"ready","headline":"Entero Therapeutics replaces Interim CEO; appoints Jason D. Sawyer","event_type":"leadership","confidence":"high","bullets":["Richard Joel Paolone terminated as Interim CEO and Chairman, effective Sept 3, 2025, without cause.","Paolone remains as director; consulting agreement terminated with payment in lieu of notice.","Jason D. Sawyer appointed Interim CEO effective Sept 4, 2025; continues as director.","Sawyer has 32-year investment background; currently Head of Finance & M&A at Quantum BioPharma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139089,"accession_number":"0001104659-25-079322","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Entero Therapeutics announces 1-for-3 reverse stock split to regain Nasdaq compliance","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at ratio 1-for-3 effective 12:01 a.m. ET on August 18, 2025.","Outstanding shares reduce from ~4.77 million to ~1.59 million; no fractional shares issued.","Split intended to raise bid price above $1.00 to satisfy Nasdaq Listing Rule 5550(a)(2).","Trading symbol remains ENTO; new CUSIP is 33749P507.","Interim CEO Richard Paolone states split is necessary to maintain Nasdaq listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139088,"accession_number":"0001104659-25-075970","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["1.01","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Entero Therapeutics raises $3M in private placement; appoints two new directors","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $3.0M from sale of pre-funded warrants and common warrants priced at $0.6149 per unit.","$1M paid at closing (Aug 11, 2025); remaining $2M due upon effectiveness of resale registration statement.","Pre-funded warrants exercisable at $0.00001; common warrants at $0.3649, expire 5 years after registration effective.","Geordan Pursglove and Jason Sawyer appointed to Board effective Aug 11, 2025; each receives $2,500/month cash retainer.","Net proceeds for general corporate purposes and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139087,"accession_number":"0001104659-25-068362","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Entero Therapeutics amends rescission agreement adding accredited investor reps from ImmunogenX shareholders","event_type":"other","confidence":"high","bullets":["Amendment adds Section 5(f) to Rescission Agreement, requiring each shareholder to be an accredited investor under Rule 501 of Regulation D.","Shareholders also represent they have no need for liquidity, have evaluated investment risks, and are acquiring Membership Units for own account.","Amendment effective July 15, 2025; parties include Entero Therapeutics, ImmunogenX LLC, and former ImmunogenX shareholders.","Original Rescission Agreement, disclosed March 25, 2025, unwound the merger between Entero and ImmunogenX."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139086,"accession_number":"0001104659-25-066418","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Entero Therapeutics regains Nasdaq annual meeting compliance","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter confirming compliance with Listing Rule 5620(a) after holding Annual Meeting on June 30, 2025.","Matter is now closed; no further action required from Nasdaq.","Company had previously reported the meeting in a Form 8-K filed July 2, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139085,"accession_number":"0001104659-25-065274","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Entero Therapeutics shareholders approve reverse stock split authorization at annual meeting","event_type":"other_material","confidence":"high","bullets":["Stockholders authorized a reverse stock split at ratio between 1:2 and 1:20, with board discretion to set ratio within one year.","Re-elected directors Edward J. Borkowski, Richard Paolone, Eric Corbett, Manpreet Uppal, and Jack Syage.","Ratified Machias Gini & O'Connell LLP as independent auditor for fiscal year ending December 31, 2025.","Advisory vote on named executive officer compensation passed with 415,176 for, 77,434 against (excluding broker non-votes).","All five proposals were approved; broker non-votes totaled 1,328,218 on director elections and advisory compensation vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156598,"accession_number":"0001104659-25-064144","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nasdaq grants Entero Therapeutics extension to Oct 8, 2025 to meet minimum equity requirement","event_type":"regulatory","confidence":"high","bullets":["Company received Nasdaq extension letter on June 25, 2025; deadline to regain compliance is October 8, 2025.","Must meet Nasdaq Rule 5550(b)(1) minimum stockholders' equity of $2.5 million.","As of Dec 31, 2024, stockholders' equity was negative $3.88 million, triggering the deficiency.","Failure to regain compliance may result in delisting, but appeal to a Nasdaq Hearing Panel is permitted.","No assurance that compliance will be achieved or listing maintained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156597,"accession_number":"0001104659-25-048544","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["1.01","2.03","5.08","9.01"],"status":"ready","headline":"Entero Therapeutics subsidiary settles litigation, restructures $7.9M debt with $5.5M payment and new revolving loan","event_type":"litigation","confidence":"high","bullets":["ImmunogenX subsidiary settled lawsuit with Mattress Liquidators; guarantors paid $5.5M of ~$7.9M owed on Apr 9, 2025.","New revolving loan of $2.44M to ImmunogenX matures Apr 9, 2028; security interest in subsidiary released.","Lawsuit to be dismissed with prejudice; ImmunogenX responsible for ~$62,000 in plaintiff's legal fees.","Annual meeting June 27, 2025; stockholder proposals/director nominations due by May 23, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156596,"accession_number":"0001104659-25-034689","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Entero Therapeutics receives Nasdaq deficiency notice for stockholders' equity shortfall","event_type":"other_material","confidence":"high","bullets":["Stockholders' equity of ($3,876,738) as of Dec 31, 2024, well below Nasdaq's $2.5M minimum.","Company also failed alternative compliance standards for market value or net income.","Must submit compliance plan by May 26, 2025; Nasdaq may grant extension to Oct 8, 2025.","Company intends to submit a plan, but no assurance of acceptance or regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175024,"accession_number":"0001104659-25-027770","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Entero Therapeutics rescinds 2024 ImmunogenX merger, retains $695K AP; names new CFO","event_type":"other_material","confidence":"high","bullets":["Rescission Agreement with ImmunogenX LLC signed March 24, 2025; unwinds the March 2024 merger.","Closing conditions include shareholder approval by June 30, 2025, lender consent, and resignation of director Jack Syage.","Company retains ~$695,000 of ImmunogenX accounts payable; ImmunogenX remains responsible for ~$9.28M secured debt.","Anna Skowron appointed CFO effective March 3, 2025; brings 14+ years of accounting and financial reporting experience.","CEO states rescission strengthens balance sheet and refocuses value creation strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175023,"accession_number":"0001104659-25-021728","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["1.01","5.02","3.01","9.01"],"status":"ready","headline":"Nasdaq extends Entero bid price compliance to Sept 1, 2025; CFO resigns, Skowron named CFO","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted extension until Sept 1, 2025 to regain $1.00 minimum bid price compliance.","CFO Sarah Romano resigned effective March 7; Anna Skowron appointed CFO at $8,333/month.","CEO Richard Paolone's consulting agreement formalized, paying $12,500/month retroactive to Feb 12.","Nasdaq extended annual meeting compliance deadline to June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}